CD19 and acute lymphoblastic leukemia: These results show that CAR-T cells have potent cytoreductive capacity in MM but unlike in anti-CD19 CARs in acute lymphoblastic leukemia (ALL) or diffuse large B cell lymphoma (DLBCL), it may not provide long-term immune surveillance against relapsed MM and may not render MM curable.